TDOC 8-K
Teladoc Health, Inc. (TDOC)
8-K
2026-08-03
For: 2026-08-03
View Original
Added on
August 03, 2026
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________________________
FORM 8-K
___________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) August 3, 2026
___________________________________
(Exact name of registrant as specified in its charter)
___________________________________
(State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) | ||||||
(Address of principal executive offices and zip code) | ||||||||
( | ||||||||
(Registrant's telephone number, including area code) | ||||||||
___________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act: | ||||||||
Title of each class | Trading Symbol | Name of each exchange on which registered | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Effective August 3, 2026, the Board of Directors (the “Board”) of Teladoc Health, Inc. (the “Company”) increased the number of directors on the Board to ten and appointed Mark V. Anquillare as a director of the Company. Mr. Anquillare was additionally appointed to each of the audit committee and the compensation committee of the Board. The Board has determined that Mr. Anquillare is an independent director within the meaning of the New York Stock Exchange listing standards and is an “audit committee financial expert” under Securities and Exchange Commission (the “SEC”) and New York Stock Exchange rules.
There are no arrangements or understandings between Mr. Anquillare and any other person pursuant to which he was selected as a director. There are no transactions involving the Company and Mr. Anquillare that the Company would be required to report pursuant to Item 404(a) of Regulation S-K.
Mr. Anquillare will have the same director indemnification arrangement as do the Company’s other directors appointed since October 2020, the form of agreement for which was filed with the SEC on March 1, 2021 as Exhibit 10.2 to the Company’s Annual Report on Form 10-K. Mr. Anquillare will be eligible to participate in the compensation arrangements and programs that are established for the Company’s non-employee directors, as in effect from time to time, which are described in the Company’s Proxy Statement on Schedule 14A filed with the SEC on April 7, 2026.
Item 7.01 Regulation FD.
On August 3, 2026, the Company issued a press release regarding the matter discussed in Item 5.02 of this Current Report. A copy of the press release is furnished herewith as Exhibit 99.1.
The information furnished under this Item 7.01 of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. | Description | ||||||||||
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). | ||||||||||
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: August 3, 2026
Teladoc Health, Inc. | |||||
By: | /s/ Adam C. Vandervoort | ||||
Name: | Adam C. Vandervoort | ||||
Title: | Chief Legal Officer and Secretary | ||||
Exhibit 99.1
Teladoc Health Appoints Financial Executive Mark Anquillare to Its Board of Directors
NEW YORK, August 3, 2026 -- Teladoc Health (NYSE: TDOC), the global leader in virtual care, today announced the appointment of Mark V. Anquillare to its board of directors. Mr. Anquillare is the former president and chief operating officer of Verisk Analytics, a strategic data analytics and technology partner to the global insurance industry. He will serve on the board’s Audit & Compensation committees.
“Mark’s leadership across the global insurance and analytics sectors, along with his experience guiding public companies through growth and transformation, makes him an outstanding addition to the Board," said Kenneth H. Paulus, non-executive Chairman of the Teladoc Health board. "His perspective on how data, technology and AI are reshaping complex industries will be invaluable as Teladoc Health evolves."
Mr. Anquillare has more than 30 years of financial and executive leadership experience. He served as Verisk’s chief financial officer beginning in 2007, leading the company through its 2009 initial public offering, and later served as Verisk’s chief operating officer, overseeing the company’s insurance and government-facing business as well as several corporate functions.
Throughout his career, Mr. Anquillare has helped companies drive growth, innovation and operating efficiency. He currently serves on the board of Guidewire Software where he chairs the audit committee and is a member of the business opportunities committee. He also serves on the boards of RegEd and Bamboo Insurance, and he previously served on the board of TruBridge. Mr. Anquillare holds an MBA from Rutgers Business School and a BBA from the University of Notre Dame.
“Teladoc Health is uniquely positioned to help healthcare become more connected, intelligent and accessible. I look forward to working with the Board and management team as the company advances innovation and creates long-term value,” said Anquillare.
About Teladoc Health
Teladoc Health (NYSE: TDOC) is the global leader in virtual care. The company is delivering and orchestrating care across patients, care providers, platforms, and partners — transforming virtual care into a catalyst for how better health happens. Through our relationships with health plans, employers, providers, health systems and consumers, we are enabling more access, driving better outcomes, extending provider capacity and lowering costs. Learn more at teladochealth.com.
Teladoc Health (NYSE: TDOC) is the global leader in virtual care. The company is delivering and orchestrating care across patients, care providers, platforms, and partners — transforming virtual care into a catalyst for how better health happens. Through our relationships with health plans, employers, providers, health systems and consumers, we are enabling more access, driving better outcomes, extending provider capacity and lowering costs. Learn more at teladochealth.com.